Skip to content

Azithromycin and prevention of bronchopulmonary dysplasia

Efficacy of Azithromycin in prevention of bronchopulmonary dysplasia in premature newborn infants

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT138902223915N1
Enrollment
100
Registered
2011-01-03
Start date
2010-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchopulmonary dysplasia, need for oxygen beyond 28 days of birth. bronchopulmonary dysplasia originating in perinatal period

Interventions

Intervention 1: Azithromycin, orally, from 7th day of birth for one week with a single dose of 10 mg/kg/daily and then 5 mg/kg/daily for subsequent week. Intervention 2: Control group: no intervention
Treatment - Drugs
Azithromycin, orally, from 7th day of birth for one week with a single dose of 10 mg/kg/daily and then 5 mg/kg/daily for subsequent week
Control group: no intervention

Sponsors

Pediatric Health Research Center, Tabriz University of Medical Sciences,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 120 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: birth weight less than 1500g, feeding starting before 7 days, parental consent for study Exclusion criteria: major congenital anomalies, congenital heart disease, chromosomal defects, death before 7th day of birth, sign of necrotising enterocolitis before 7th day of birth, severe intraventricular hemorrhage (grade 3 or 4)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Duration of need for oxygen. Timepoint: daily. Method of measurement: days count before O2 discontinue.;Needed FIO2. Timepoint: daily. Method of measurement: oxymeter and blender.;Spo2. Timepoint: daily. Method of measurement: pulseoxymetry.

Secondary

MeasureTime frame
Duration of hospitalization. Timepoint: days of hospital stay. Method of measurement: time between admission and discharge.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Manizheh Mostafa Gharehbaghi/ Dr Majid Mahaleii

Tabriz University of Medical Sciences

gharehbaghimm@yahoo.com/mahalei@yahoo.com+98 41 1553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026